TT-402

TT-402 is an investigational peptide-based therapeutic being developed for metabolic and endocrine indications, most notably type 2 diabetes, as part of a diabetes therapy research program at Transition Therapeutics, initially originating from work at Eli Lilly. Publicly available pipeline summaries describe TT-402 only at a high level as a pending, early-stage metabolic agent without disclosed molecular target, detailed mechanism of action, or clinical-stage data, suggesting development has not advanced beyond preclinical or very early clinical evaluation and that its precise pharmacology, route, and competitive positioning remain undisclosed.